Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia

Cancer

Volumn 103, Issue 2, 2005, Pages 368-376

  Rivera, Gaston K ^a,b   Zhou, Yinmei ^a   Hancock, Michael L ^a   Gajjar, Amar ^a   Rubnitz, Jeffrey ^a   Ribeiro, Raul G ^a,b   Sandlund, John T ^a,b   Hudson, Melissa ^a,b   Relling, Mary ^a,b   Evans, William E ^a,b   Pui, Ching Hon ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Children; Outcome; Prognostic factors; Recurrent lymphoblastic leukemia

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; HYDROCORTISONE; MACROGOL; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; BONE MARROW CANCER; BONE MARROW RECURRENCE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL LINEAGE; CHEMOTHERAPY; CHILD; DATA ANALYSIS; GENOTYPE; HUMAN; IMMUNOPHENOTYPING; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MANTEL HAENSZEL TEST; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; AGE DISTRIBUTION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; BONE MARROW; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INCIDENCE; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; NEOPLASM RECURRENCE, LOCAL; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL RATE;

EID: 19944431781     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20743     Document Type: Article

References (47)

1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535-1548.
2. Schrappe M, Reiter A, Zimmerman M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia. 2000;14:2205-2222.
3. Henze G, Fendler R, Hartmann R, et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85): a relapse study of the BFM group. Blood. 1991;78:166-1172.
4. Barrett AJ, Horowitz MM, Pollock BH, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med. 1994;331:1253-1258.
5. Pui C-H, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St. Jude Children's Research Hospital. Leukemia. 2000;14:2286-2294.
6. Behm FG, Raimondi SC, Schell MK, Look AT, Rivera GK, Pui C-H. Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukemia is associated with chromosomal hyperdiploidy and other favorable prognostic factors. Blood. 1992;79:1011-1016.
7. Mitelman F, editor. International System for Human Cytogenetic Nomenclature (ICSN): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature, Memphis, Tenn., October 1994. Basel: S. Karger, 1995:114.
8. Pinkel D. Five-year follow up of "total therapy" of childhood lymphocytic leukemia. JAMA. 1971;216:648-652.
9. Rivera GK, Raimondi SC, Hancock ML, et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet. 1991;337:61-66.
10. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998;338:499-505.
11. Pui C-H, Relling MV, Behm FG, et al. L-asparaginase may potentiate the leukemogenic effect of epipodophyllotoxins. Leukemia. 1995;9:1680-1684.
12. Kalbfleish JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons, Inc., 1980:163-188.
13. Gray RJ. A class of K-sample test for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
15. Mantel N, Byar DP. Evaluation of response-time data involving transient states: an illustration using heart-transplant data. J Am Stat Assoc. 1974;345:81-86.
16. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-450.
17. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
18. Buchanan GR, Rivera GK, Boyett JM, Chauvenet AR, Crist WM, Vietti TJ. Re-induction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study. Blood. 1988;72:1286-1292.
19. Abshire TC, Pollock BH, Billet AL, Bradley P, Buchanan GR. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood. 2000;96:1709-1715.
20. Gaynon PS, Qu RP, Chappell RJ, et al. Survival after relapse in childhood acute lymphoblastic leukemia. Cancer. 1998;82:1387-1395.
21. Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood. 2002;100:52-58.
22. Cave H, Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med. 1998;339:591-598.
23. Willemse MJ, Seriu T, Hettinger K, et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood. 2002;99:4386-4393.
24. van Dongen J, Seriu T, Panxer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731-1738.
25. Coustan-Smith E, Gajjar A, Hijiya N, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia. 2004;18:499-504,
26. Eckert C, Biondi A, Seeger K, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet. 2001;358:1239-1241.
27. Rivera GK, Hudson MM, Liu Q, et al. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. Blood. 1996;88:831-837.
28. Chessels JM, Leiper AD, Richards SM. A second course of treatment for childhood acute lymphoblastic leukemia: long term follow up is needed to assess results. Br J Haematol. 1994;86:48-54.
29. Borgmann A, von Stackelberg A, Hartmann R, et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood. 2003;101:3835-3839.
30. von Stackelberg A, Hartmann R, Herold R, et al. Outcome after relapse of T-cell acute lymphoblastic leukemia in childhood. A report from the BFM Relapse Study Group [abstract]. Med Pediatr Oncol. 2000;35:250.
31. Beyermann B, Agthe AG, Adams HP, et al. Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukemia expressing BCR-ABL fusion transcripts. Blood. 1996;87:1532-1538.
32. Loh ML, Silverman LB, Young ML, et al. Incidence of TEL-AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood. 1998;92:4792-4797.
33. Rubnitz JE, Behm FG, Wichlan D, et al. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. Leukemia. 1999;13:19-21.
34. Seeger K, von Stackelberg A, Taube T, et al. Relapse of TEL-AML1-positive acute lymphoblastic leukemia in childhood: a matched-pair analysis. J Clin Oncol. 2001;19:3188-3193.
35. Buhrer C, Hartmann R, Fengler R, et al. Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1993;21:470-476.
36. Pui C-H, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92:411-415.
37. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663-1671.
38. Maloney DH, Shuster JJ, Nitschke R, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group Phase III Trial. J Clin Oncol. 1998;16:246-254.
39. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310-3322.
40. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana Farber Consortium Protocol 91-01. Blood. 2001;97:1211-1218.
41. Pui C-H, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St. Jude Children's Research Hospital. Blood. 2004;104:2690-2696.
42. Melnick A, Licht JD. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167-3215.
43. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
44. Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003;3:173-183.
45. Yeoh EJ, Ross ME, Shurtleff S, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1:133-143.
46. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1:1-13.
47. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351:533-542.